Ratings Organogenesis Holdings Inc. Nasdaq

Equities

AHPAU

KYG0726L1095

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+1.51%	+0.58%

May. 02	Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis	CI
Feb. 29	Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's profit outlook over the next few years is a strong asset.
The stock, which is currently worth 2024 to 0.68 times its sales, is clearly overvalued in comparison with peers.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ORGANOGENESIS HOLDINGS INC.	+0.58%	317M	-
MODERNA, INC.	+21.74%	46.81B	B-
IQVIA HOLDINGS INC.	-0.97%	41.37B	B
LONZA GROUP AG	+47.07%	41.29B	A
CELLTRION, INC.	-3.52%	28.87B	C
ICON PUBLIC LIMITED COMPANY	+11.12%	26.06B	B-
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.13B	B
MEDPACE HOLDINGS, INC.	+31.18%	12.39B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.08B	C+
BIO-TECHNE CORPORATION	+0.39%	11.96B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes